China FDA issues device guidelines, highlights training for inspectors

China flag

China FDA has released a slew of new standards for medical devices as it ramps up training of inspectors to oversee the industry.

In a notice in early May, China FDA said it had released 186 industry standards under two orders covering medical devices, which include 42 mandatory guidelines and 144 recommendations for the industry.

The guidelines cover everything from implants and disinfectant procedures to equipment across specialties such as dental and ophthalmic tools.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“The promulgation and implementation of these standards will further improve China's medical device standards system, and build a solid foundation for ensuring the safety and effectiveness of medical devices and protecting the health of the public,” CFDA said in a statement.

The regulator has also said it has completed the first round of a continuing education program of medical equipment inspectors, which includes certificates covering a range of subjects such as good manufacturing practices, and also included discussions with unspecified regulators from abroad.

- here's the China FDA release on device standards
- and the China FDA notice on the device inspector training (in Chinese)

Read more on

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.